#foundation models
Total 6 articles
Chai Discovery's $1.3B valuation isn't just a funding round. It's proof that AI is moving from chatbots to designing life, creating a new breed of AI-native biotech.
Chai Discovery's $1.3B valuation, backed by OpenAI, isn't just a funding round. It's a signal that AI is set to industrialize drug creation, challenging Big Pharma's core model.
PRISM by Liabooks
Place your ad in this space
[email protected]
Chai Discovery's $130M raise at a $1.3B valuation isn't about a single drug. It's a strategic move by OpenAI's ecosystem to build the dominant AI platform for biotech.
Chai Discovery's $130M raise at a $1.3B valuation isn't about a single drug. It's a strategic move by OpenAI's ecosystem to build the dominant AI platform for biotech.
Chai Discovery's $130M raise at a $1.3B valuation isn't a funding story. It's a signal that elite AI talent is targeting pharma's core business model.
